Get started
Author

Erica Cheng

Differential Transgene Silencing of Myeloid-Specific Promoters in the AAVS1 Safe Harbor Locus of Induced Pluripotent Stem Cell-Derived Myeloid Cells
2019 · Denise Klatt, Erica Cheng, et al. · Human Gene Therapy · 50
Targeted Repair of p47-CGD in iPSCs by CRISPR/Cas9: Functional Correction without Cleavage in the Highly Homologous Pseudogenes
2019 · Denise Klatt, Erica Cheng, et al. · Stem Cell Reports · 28
PDF
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme
2023 · Tim Raine, Yoh Ishiguro, et al. · Journal of Crohn s and Colitis · 8
PDF
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
2024 · Stefan Schreiber, Raymond K. Cross, et al. · Alimentary Pharmacology & Therapeutics · 3
PDF
S1984 Efficacy of Retreatment With Upadacitinib After Treatment Interruption in Ulcerative Colitis: Data From the U-ACTIVATE Open-Label Extension
2025 · Remo Panaccione, Jean-Frederic Colombel, et al. · The American Journal of Gastroenterology · 1
Wirksamkeit und Sicherheit von Upadacitinib nach 5-jähriger Behandlung von Patienten mit mittelschwerer bis schwerer Colitis ulcerosa: Zwischenanalyse der Open Label Phase-3-Verlängerungsstudie U-ACTIVATE
2026 · R Panaccione, J-F Colombel, et al. · Zeitschrift für Gastroenterologie
P232 Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: U-ACTIVATE
2026 · Remo Panaccione, Gary Lichtenstein, et al. · E-Posters
Tu1645 EFFICACY AND SAFETY OF UPADACITINIB AFTER 5 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM ANALYSIS FROM THE PHASE 3 UACTIVATE OPEN-LABEL EXTENSION STUDY
2026 · Remo Panaccione, Jean Frederic Colombel, et al. · Gastrointestinal Endoscopy
Tu1645 EFFICACY AND SAFETY OF UPADACITINIB AFTER 5 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM ANALYSIS FROM THE PHASE 3 UACTIVATE OPEN-LABEL EXTENSION STUDY
2026 · Remo Panaccione, Jean Frederic Colombel, et al. · Gastroenterology
DOP056 Efficacy and Safety of Upadacitinib After 5 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Analysis From the Phase 3 U-ACTIVATE Open-Label Extension Study
2026 · R Panaccione, J F Colombel, et al. · Journal of Crohn s and Colitis
P1156 Association Between Histologic and Endoscopic Outcomes With Long-Term Clinical and Symptomatic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Upadacitinib
2026 · F Magro, V Jairath, et al. · Journal of Crohn s and Colitis
PDF
Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study
2026 · Remo Panaccione, Jean-Frédéric Colombel, et al. · Gastro Hep Advances
PDF
46 Association Between Induction Response and Maintenance Dosing: A Post-Hoc Analysis of Upadacitinib-Treated Patients With Crohn’s Disease and Ulcerative Colitis
2025 · Bruno Silva, Maithili Chitnavis, et al. · The American Journal of Gastroenterology
Su1841: EFFICACY AND SAFETY OF UPADACITINIB AFTER 4 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
2025 · Remo Panaccione, Gary R. Lichtenstein, et al. · Gastroenterology
S1080 Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE
2024 · Marla Dubinsky, Raja Atreya, et al. · The American Journal of Gastroenterology
P120 Upadacitinib for moderate-to-severe ulcerative colitis: interim results from U-ACTIVATE phase III open-label extension
2024 · Remo Panaccione, Peter DR Higgins, et al. · Poster presentations
Tu1451: ACHIEVEMENT OF STEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE DURING TREATMENT WITH RISANKIZUMAB
2022 · Stefan Schreiber, Raymond K. Cross, et al. · Gastroenterology
Tu1479: NORMALISATION OF BIOMARKERS AND IMPROVEMENT IN CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE TREATED WITH RISANKIZUMAB IN THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
2022 · Raja Atreya, Brian G. Feagan, et al. · Gastroenterology
Tu1448: EFFECT OF BASELINE DISEASE CHARACTERISTICS ON CLINICAL OUTCOMES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH UPADACITINIB: RESULTS FROM A PHASE 3 TRIALS PROGRAMME
2022 · Peter D. Higgins, Jean Frederic Colombel, et al. · Gastroenterology
Tu1471: IMPACT OF CORTICOSTEROID USAGE ON EFFICACY AND SAFETY OUTCOMES IN PATIENTS RECEIVING UPADACITINIB FOR ULCERATIVE COLITIS
2022 · Tim Raine, Yoh Ishiguro, et al. · Gastroenterology
Works count: 20
Citation count: 90
H-index: 3
I10-index: 2
Year
Topic
Type